AlphaQuest LLC increased its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 49,687.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,983 shares of the biopharmaceutical company's stock after acquiring an additional 3,975 shares during the quarter. AlphaQuest LLC's holdings in Intra-Cellular Therapies were worth $333,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also recently bought and sold shares of ITCI. Assetmark Inc. raised its position in shares of Intra-Cellular Therapies by 9.1% in the 3rd quarter. Assetmark Inc. now owns 2,477 shares of the biopharmaceutical company's stock valued at $181,000 after purchasing an additional 207 shares in the last quarter. Atria Investments Inc raised its holdings in Intra-Cellular Therapies by 41.1% in the third quarter. Atria Investments Inc now owns 5,137 shares of the biopharmaceutical company's stock valued at $376,000 after acquiring an additional 1,497 shares in the last quarter. Versor Investments LP acquired a new stake in Intra-Cellular Therapies in the third quarter valued at $257,000. Entropy Technologies LP bought a new position in Intra-Cellular Therapies during the 3rd quarter valued at $521,000. Finally, MQS Management LLC acquired a new position in Intra-Cellular Therapies during the 3rd quarter worth $269,000. Hedge funds and other institutional investors own 92.33% of the company's stock.
Analyst Upgrades and Downgrades
Several equities analysts have recently commented on ITCI shares. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $132.00 price target (up previously from $108.00) on shares of Intra-Cellular Therapies in a research report on Wednesday, January 22nd. Leerink Partnrs downgraded Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a report on Monday, January 13th. Needham & Company LLC reiterated a "hold" rating on shares of Intra-Cellular Therapies in a report on Friday, February 21st. StockNews.com assumed coverage on Intra-Cellular Therapies in a research report on Wednesday, March 12th. They set a "hold" rating on the stock. Finally, Piper Sandler reaffirmed a "neutral" rating and issued a $132.00 price objective (up previously from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Ten analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $106.08.
Read Our Latest Stock Analysis on Intra-Cellular Therapies
Intra-Cellular Therapies Price Performance
NASDAQ:ITCI remained flat at $131.45 during mid-day trading on Tuesday. 1,468,263 shares of the company traded hands, compared to its average volume of 1,326,628. Intra-Cellular Therapies, Inc. has a 12-month low of $63.87 and a 12-month high of $131.47. The stock has a market capitalization of $13.98 billion, a PE ratio of -151.09 and a beta of 0.69. The stock's 50 day moving average is $124.95 and its 200 day moving average is $96.11.
Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last announced its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The business had revenue of $199.22 million for the quarter, compared to the consensus estimate of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. Equities research analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.
Intra-Cellular Therapies Company Profile
(
Free Report)
Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.
Featured Stories
Before you consider Intra-Cellular Therapies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intra-Cellular Therapies wasn't on the list.
While Intra-Cellular Therapies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
